Search

Your search keyword '"Shimokawa, Hiroaki"' showing total 1,418 results
Start Over Author "Shimokawa, Hiroaki" Publication Year Range Last 10 years
1,418 results on '"Shimokawa, Hiroaki"'

6. Mitral regurgitation is associated with similar loss of von Willebrand factor large multimers but lower frequency of anemia compared with aortic stenosis

Author

Takiguchi, Hiroshi, Miura, Mizuki, Shirai, Shin-ichi, Soga, Yoshimitsu, Hanyu, Michiya, Sakaguchi, Genichi, Soga, Yoshiharu, Arai, Yoshio, Watanabe, Shin, Kimura, Takeshi, Takahama, Hiroyuki, Yasuda, Satoshi, Nakayoshi, Takaharu, Fukumoto, Yoshihiro, Yaoita, Nobuhiro, Shimokawa, Hiroaki, Sakatsume, Ko, Saiki, Yoshikatsu, Kaikita, Koichi, Tsujita, Kenichi, Tamura, Toshihiro, Doman, Tsuyoshi, Yamashita, Mihoko, Suzuki, Misako, Eura, Yuka, Kokame, Koichi, Hayakawa, Masaki, Matsumoto, Masanori, Okubo, Noriyuki, Sugawara, Shingo, Fujimaki, Shin-ichi, Kawate, Yasunori, Ando, Kenji, and Horiuchi, Hisanori

Published
2024
Full Text
View/download PDF

9. Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease

Author

Hibi, Kiyoshi, Gohbara, Masaomi, Uemura, Kohei, Iwahashi, Noriaki, Okada, Kozo, Iwata, Hiroshi, Fukumoto, Yoshihiro, Hiro, Takafumi, Ozaki, Yukio, Iimuro, Satoshi, Sakuma, Ichiro, Hokimoto, Seiji, Miyauchi, Katsumi, Matsuyama, Yutaka, Nakagawa, Yoshihisa, Ogawa, Hisao, Daida, Hiroyuki, Shimokawa, Hiroaki, Saito, Yasushi, Kimura, Takeshi, Matsuzaki, Masunori, Kimura, Kazuo, and Nagai, Ryozo

Published
2024
Full Text
View/download PDF

10. von Willebrand factor Ristocetin co-factor activity to von Willebrand factor antigen level ratio for diagnosis of acquired von Willebrand syndrome caused by aortic stenosis

Author

Okubo, Noriyuki, Sugawara, Shingo, Fujiwara, Tohru, Sakatsume, Ko, Doman, Tsuyoshi, Yamashita, Mihoko, Goto, Kota, Tateishi, Masaki, Suzuki, Misako, Shirakawa, Ryutaro, Eura, Yuka, Kokame, Koichi, Hayakawa, Masaki, Matsumoto, Masanori, Kawate, Yasunori, Miura, Mizuki, Takiguchi, Hiroshi, Soga, Yoshimitsu, Shirai, Shinichi, Ando, Kenji, Arai, Yoshio, Nakayoshi, Takaharu, Fukumoto, Yoshihiro, Takahama, Hiroyuki, Yasuda, Satoshi, Tamura, Toshihiro, Watanabe, Shin, Kimura, Takeshi, Yaoita, Nobuhiro, Shimokawa, Hiroaki, Saiki, Yoshikatsu, Kaikita, Koichi, Tsujita, Kenichi, Yoshii, Shinji, Nakase, Hiroshi, Fujimaki, Shin-ichi, and Horiuchi, Hisanori

Published
2024
Full Text
View/download PDF

13. JCS/CVIT/JCC 2023 guideline focused update on diagnosis and treatment of vasospastic angina (coronary spastic angina) and coronary microvascular dysfunction

Author

Hokimoto, Seiji, Kaikita, Koichi, Yasuda, Satoshi, Tsujita, Kenichi, Ishihara, Masaharu, Matoba, Tetsuya, Matsuzawa, Yasushi, Mitsutake, Yoshiaki, Mitani, Yoshihide, Murohara, Toyoaki, Noda, Takashi, Node, Koichi, Noguchi, Teruo, Suzuki, Hiroshi, Takahashi, Jun, Tanabe, Yasuhiko, Tanaka, Atsushi, Tanaka, Nobuhiro, Teragawa, Hiroki, Yasu, Takanori, Yoshimura, Michihiro, Asaumi, Yasuhide, Godo, Shigeo, Ikenaga, Hiroki, Imanaka, Takahiro, Ishibashi, Kohei, Ishii, Masanobu, Ishihara, Takayuki, Matsuura, Yunosuke, Miura, Hiroyuki, Nakano, Yasuhiro, Ogawa, Takayuki, Shiroto, Takashi, Soejima, Hirofumi, Takagi, Ryu, Tanaka, Akihito, Taruya, Akira, Tsuda, Etsuko, Wakabayashi, Kohei, Yokoi, Kensuke, Minamino, Toru, Nakagawa, Yoshihisa, Sueda, Shozo, Shimokawa, Hiroaki, and Ogawa, Hisao

Published
2023
Full Text
View/download PDF

14. Differential prediction of high-sensitivity cardiac troponin-I, but not N-terminal pro-brain natriuretic peptide, in different pitavastatin doses on cardiovascular events in stable coronary artery disease

Author

Mitsutake, Yoshiaki, Ishii, Junnichi, Fukumoto, Yoshihiro, Ito, Sohei, Kashiwabara, Kosuke, Uemura, Kouhei, Matsuyama, Yutaka, Sugiyama, Yoichi, Ozaki, Yukio, Iimuro, Satoshi, Iwata, Hiroshi, Sakuma, Ichiro, Nakagawa, Yoshihisa, Hibi, Kiyoshi, Hiro, Takafumi, Hokimoto, Seiji, Miyauchi, Katsumi, Daida, Hiroyuki, Shimokawa, Hiroaki, Saito, Yasushi, Kimura, Takeshi, Matsuzaki, Masunori, and Nagai, Ryozo

Published
2023
Full Text
View/download PDF

18. Usefulness of cardiac magnetic resonance for early detection of cancer therapeutics-related cardiac dysfunction in breast cancer patients

Author

Terui, Yosuke, Sugimura, Koichiro, Ota, Hideki, Tada, Hiroshi, Nochioka, Kotaro, Sato, Haruka, Katsuta, Yuko, Fujiwara, Junko, Harada-Shoji, Narumi, Sato-Tadano, Akiko, Morita, Yoshiaki, Sun, Wenyu, Higuchi, Satoshi, Tatebe, Shunsuke, Fukui, Shigefumi, Miyamichi-Yamamoto, Saori, Suzuki, Hideaki, Yaoita, Nobuhiro, Kikuchi, Nobuhiro, Sakota, Miku, Miyata, Satoshi, Sakata, Yasuhiko, Ishida, Takanori, Takase, Kei, Yasuda, Satoshi, and Shimokawa, Hiroaki

Published
2023
Full Text
View/download PDF

27. Plasma ANGPTL8 Levels and Risk for Secondary Cardiovascular Events in Japanese Patients With Stable Coronary Artery Disease Receiving Statin Therapy

Author

Morinaga, Jun, Kashiwabara, Kosuke, Torigoe, Daisuke, Okadome, Yusuke, Aizawa, Kenichi, Uemura, Kohei, Kurashima, Ai, Matsunaga, Eiji, Fukami, Hirotaka, Horiguchi, Haruki, Sato, Michio, Sugizaki, Taichi, Miyata, Keishi, Kadomatsu, Tsuyoshi, Mukoyama, Masashi, Miyauchi, Katsumi, Hokimoto, Seiji, Fukumoto, Yoshihiro, Hiro, Takafumi, Hibi, Kiyoshi, Nakagawa, Yoshihisa, Sakuma, Ichiro, Ozaki, Yukio, Iwata, Hiroshi, Iimuro, Satoshi, Daida, Hiroyuki, Shimokawa, Hiroaki, Kimura, Takeshi, Matsuzaki, Masunori, Saito, Yasushi, Matsuyama, Yutaka, Nagai, Ryozo, and Oike, Yuichi

Published
2023
Full Text
View/download PDF

32. Age‐stratified profiles and outcomes of patients with heart failure with preserved ejection fraction.

Author

Yamanaka, Shinsuke, Nochioka, Kotaro, Hayashi, Hideka, Shiroto, Takashi, Takahashi, Jun, Miyata, Satoshi, Yasuda, Satoshi, and Shimokawa, Hiroaki

Subjects
CARDIAC arrest, HEART failure patients, GLYCEMIC control, VENTRICULAR ejection fraction, CORONARY artery disease
Abstract

Aims: This study aimed to elucidate age‐stratified clinical profiles and outcomes in patients with heart failure (HF) with preserved left ventricular ejection fraction (LVEF) (HFpEF). Methods and results: The Chronic Heart Failure Registry and Analysis in the Tohoku District‐2 (CHART‐2) Study included 2824 consecutive HFpEF patients with LVEF ≥ 50% (mean age 69.0 ± 12.3 years; 67.7% male) with a median follow‐up of 9.8 years. We stratified them into five age groups: ≤54 (N = 349, 12.4%), 55–64 (N = 529, 18.7%), 65–74 (N = 891, 31.6%), 75–84 (N = 853, 30.2%), and ≥85 years (N = 202, 7.2%), and we categorized these age groups into younger (≤64 years) and older (≥65 years) groups. We compared the clinical profiles and outcomes of HFpEF patients across age groups. Younger HFpEF groups exhibited a male predominance, elevated body mass index (BMI), and poorly controlled diabetes (haemoglobin A1c > 7.0%). Older HFpEF groups were more likely to be female with multiple comorbidities, including coronary artery disease, hypertension, renal impairment, and atrial fibrillation. The positive association between elevated BMI and HFpEF was more pronounced with lower classes of age from ≥85 to ≤54 years, especially in males. With higher classes of age from ≤54 to ≥85 years, mortality rates increased, and HF death became proportionally more prevalent (Ptrend < 0.001), whereas sudden cardiac death (SCD) exhibited the opposite trend (Ptrend = 0.002). Poorly controlled diabetes emerged as the only predictor of SCD in the younger groups (adjusted hazard ratio 4.26; 95% confidence interval 1.45–12.5; P = 0.008). Multiple comorbidities were significantly associated with an increased risk of HF‐related mortality in the older groups. Conclusions: Younger HFpEF patients (≤64 years) exhibit a male predominance, elevated BMI, and poorly controlled diabetes, highlighting the importance of glycaemic control in reducing SCD risk. Older HFpEF patients (≥65 years) are more likely to be female, with multiple comorbidities linked to an increased risk of HF‐related mortality. These findings underscore the need for physicians to recognize age‐related, distinct HFpEF phenotypes for personalized patient management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study

Author

Kamiya, Kiwamu, primary, Takei, Makoto, additional, Nagai, Toshiyuki, additional, Miyoshi, Toru, additional, Ito, Hiroshi, additional, Fukumoto, Yoshihiro, additional, Obara, Hitoshi, additional, Kakuma, Tatsuyuki, additional, Sakuma, Ichiro, additional, Daida, Hiroyuki, additional, Iimuro, Satoshi, additional, Shimokawa, Hiroaki, additional, Kimura, Takeshi, additional, Nagai, Ryozo, additional, and Anzai, Toshihisa, additional

Published
2024
Full Text
View/download PDF

36. Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy

Author

Abe, Mitsuru, Ozaki, Yukio, Takahashi, Hiroshi, Ishii, Mitsuru, Masunaga, Nobutoyo, Ismail, Tevfik F., Iimuro, Satoshi, Fujita, Retsu, Iwata, Hiroshi, Sakuma, Ichiro, Nakagawa, Yoshihisa, Hibi, Kiyoshi, Hiro, Takafumi, Fukumoto, Yoshihiro, Hokimoto, Seiji, Miyauchi, Katsumi, Ogawa, Hisao, Daida, Hiroyuki, Shimokawa, Hiroaki, Saito, Yasushi, Matsuzaki, Masunori, Akao, Masaharu, Kimura, Takeshi, and Nagai, Ryozo

Published
2021
Full Text
View/download PDF

43. Prognostic significance of growth differentiation factor‐15 across age in chronic heart failure.

Author

Teramoto, Kanako, Nochioka, Kotaro, Sakata, Yasuhiko, Nishimura, Kunihiro, Shimokawa, Hiroaki, and Yasuda, Satoshi

Subjects
HEART failure, BRAIN natriuretic factor, TRANSFORMING growth factors, ACE inhibitors, SYSTOLIC blood pressure, GLOMERULAR filtration rate
Abstract

Aims: Growth differentiation factor‐15 (GDF15), a cytokine in the transforming growth factor family, is up‐regulated in stress and inflammatory conditions and is elevated in patients with heart failure (HF). However, the age‐specific attributes and prognostic significance of GDF15 across age remain unknown in chronic HF (CHF). Methods and results: Serum levels of GDF15 were examined in 942 hypertensive patients (median 68 years) with CHF from the SUPPORT trial across the four age groups [under 50 (n = 73), 51–59 (n = 158), 60–69 (n = 296), and 70–79 years (n = 415)] and in the continuous spectrum. Clinical correlates of GDF15 were explored using the classic stepwise and LASSO (least absolute shrinkage and selection operator) regression approaches. Interaction terms with age were tested in the LASSO regression approach. The associations with the composite outcome of HF hospitalization or all‐cause death were investigated across ages. Median GDF15 levels (pg/mL) increased along with aging, from 691 in under 50 years to 855 in 51–59 years, 1114 in 60–69 years, and 1516 in 70–79 years (trend P < 0.001). Age, sex, systolic blood pressure, history of diabetes, ischaemic heart disease, left ventricular (LV) end‐systolic dimension, LV ejection fraction, estimated glomerular filtration rate, haemoglobin, N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), troponin, C‐reactive protein, and the use of angiotensin‐converting enzyme inhibitors, diuretics, and statins were mutually selected as clinical covariates of GDF15. The LASSO regression analysis identified significant interactions between age and the history of diabetes and NT‐proBNP, with particularly robust associations in patients aged between 60 and 70 years. During the mean follow‐up of 8.6 years, 474 composite endpoints of HF hospitalization or death occurred. GDF15 was associated with a higher risk of HF hospitalization or all‐cause death [adjusted hazard ratio 1.84 (95% confidence interval 1.45–2.33)], with a particularly heightened risk in patients aged around 70 years (Pinteraction = 0.0008). The model with GDF15 on top of other established risk factors yielded marginally higher C‐statistics compared with the model without GDF15 (0.803 and 0.796, P = 0.045). The additive value of GDF15 on top of other established risk factors appeared similar across ages. A universal cut‐off value of 1400 pg/mL performed well in discriminating between those with and without HF hospitalization or death. Conclusions: Some clinical correlates of GDF15 have an interaction with age. GDF15 is an important determinant of cardiovascular endpoints, particularly in patients aged around 70 years. The additive value of GDF15 appeared consistent across ages, suggesting the use of a universal cut‐off value. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results